Indications and Usage

Altreno® (tretinoin) Lotion, 0.05% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

Important Safety Information

Altreno is for topical use only. Not for ophthalmic, oral, or intravaginal use.

Skin Irritation: Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation.

Skin Irritation

Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation. Depending upon the severity of these adverse reactions, instruct patients to use a moisturizer, reduce the frequency of the application of Altreno, or discontinue use. Avoid application of Altreno to eczematous or sunburned skin.

Ultraviolet Light and Environmental Exposure

Minimize unprotected exposure to ultraviolet light, including sunlight and sunlamps. Warn patients with frequent sun exposure and those with inherent sensitivity to sunlight to exercise caution. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

Fish Allergies

Altreno contains soluble fish proteins. Use with caution in patients with known sensitivity or allergy to fish. Advise patients to contact their healthcare provider if they develop pruritus or urticaria.

Adverse Reactions

The most common adverse reactions in clinical trials were application site dryness (4%), pain (3%), erythema (2%), irritation (1%) and exfoliation (1%).

Nursing Women

It is not known whether topical administration of tretinoin could result in sufficient systemic absorption to produce detectable concentrations in human milk. The developmental health benefits of breastfeeding should be considered along with the mother’s clinical need for Altreno and any potential adverse effects on the breastfed child from Altreno.

To report suspected adverse reactions, contact Customer Service at 1-800-321-4576 or the FDA at 1-800-FDA-1088 or fda.gov/medwatch.

View full Prescribing Information

Skin Irritation

Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation. Depending upon the severity of these adverse reactions, instruct patients to use a moisturizer, reduce the frequency of the application of Altreno, or discontinue use. Avoid application of Altreno to eczematous or sunburned skin.

Ultraviolet Light and
Environmental Exposure

Minimize unprotected exposure to ultraviolet light, including sunlight and sunlamps. Warn patients with frequent sun exposure and those with inherent sensitivity to sunlight to exercise caution. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

Fish Allergies

Altreno contains soluble fish proteins. Use with caution in patients with known sensitivity or allergy to fish. Advise patients to contact their healthcare provider if they develop pruritus or urticaria.

Adverse Reactions

The most common adverse reactions in clinical trials were application site dryness (4%), pain (3%), erythema (2%), irritation (1%) and exfoliation (1%).

Nursing Women

It is not known whether topical administration of tretinoin could result in sufficient systemic absorption to produce detectable concentrations in human milk. The developmental health benefits of breastfeeding should be considered along with the mother’s clinical need for Altreno and any potential adverse effects on the breastfed child from Altreno.

To report suspected adverse reactions, contact Customer Service at 1-800-321-4576 or the FDA at 1-800-FDA-1088 or fda.gov/medwatch.

View Full Prescribing Information

Indications and Usage

Altreno® (tretinoin) Lotion, 0.05% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

Important Safety Information

Altreno is for topical use only. Not for ophthalmic, oral, or intravaginal use.

Skin Irritation: Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation.

For patients concerned about dryness and irritation, comes the only tretinoin in a hydrating lotion formulation

 
 

The barrier-supporting effects of the Altreno vehicle are beneficial since a properly functioning barrier is essential to re-establishing healthy skin.

Patients with different skin types will likely appreciate the hydrating effects of an easily applied topical lotion.*

*Like all tretinoins, Altreno may cause irritation.

KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO KEY INGREDIENTS IN ALTRENO

Unique Polymeric
Honeycomb Mesh
Delivery System

Altreno cellular absortion for better comfort and hydration

The Altreno polymeric honeycomb mesh helps provide a uniform distribution of both the micronized tretinoin as well as the moisturizing and hydrating ingredients (sodium hyaluronate, soluble collagen, glycerin).

What’s in Altreno?

01

Tretinoin


Tretinoin is a clinical-strength vitamin A derivative proven to treat acne to improve the quality and texture of skin.

02

Sodium Hyaluronate


Sodium Hyaluronate, a form of Hyaluronic Acid, helps keep skin moisturized throughout the day.

03

Marine Collagen


Naturally hydrate with marine collagen, derived from sole fish*, which moisturizes and hydrates skin.

04

Glycerin


Glycerin hydrates and can help protect skin from irritation and may contribute to the healing process.

01

Tretinoin


Tretinoin is a clinical-strength vitamin A derivative proven to treat acne to improve the quality and texture of skin.

02

Sodium Hyaluronate


Sodium Hyaluronate, a form of Hyaluronic Acid, helps keep skin moisturized throughout the day.

03

Marine Collagen


Naturally hydrate with marine collagen, derived from sole fish*, which moisturizes and hydrates skin.

04

Glycerin


Glycerin hydrates and can help protect skin from irritation and may contribute to the healing process.

*Use with caution in patients with known sensitivity or allergy to fish. Advise patients to contact their healthcare provider if they develop pruritus or urticaria.

Backed by 5 years of research,
development, and testing.
FDA-approved.

Proven inflammatory lesion reductions

Primary endpoints (over a 12-week period)

  • The mean absolute reduction in inflammatory lesion counts with Altreno Lotion was 13.1 vs 10.2 for vehicle (P<0.001)
  • 16.5% of patients experienced treatment success* vs 6.9% with vehicle (P<0.001)

Significant inflammatory
lesion reductions at week 12

*Treatment success was defined as at least a 2-grade improvement from baseline and an Evaluator's Global Severity Score of clear (0) or almost clear (1). Results of 2 phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group studies comparing the efficacy and safety of Altreno lotion once daily for 12 weeks with vehicle in patients 9 years and older with moderate-to-severe acne vulgaris (baseline 20 to 40 inflammatory lesions).

Backed by 5 years of research,
development, and testing.
FDA-approved.

Proven non-inflammatory lesion reductions

Primary endpoints (over a 12-week period)

  • The mean absolute reduction in comedonal lesion counts with Altreno lotion was 17.8 vs 10.6 for vehicle (P<0.001)
  • 16.5% of patients experienced treatment success* vs 6.9% with vehicle (P<0.001)

Significant non-inflammatory
lesion reductions at week 12

*Treatment success was defined as at least a 2-grade improvement from baseline and an Evaluator's Global Severity Score of clear (0) or almost clear (1). Results of 2 phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group studies comparing the efficacy and safety of Altreno lotion once daily for 12 weeks with vehicle in patients 9 years and older with moderate-to-severe acne vulgaris (baseline 20 to 40 inflammatory lesions).

Backed by 5 years of research,
development, and testing.
FDA-approved.

In a post-hoc analysis of adult women aged 18 to 54, inflammatory and
non-inflammatory acne lesion counts were reduced by almost 60%.

In adult female patients with severe acne treated with Altreno, there were numerically greater reductions in both inflammatory and noninflammatory lesion counts compared to vehicle (59.0% and 58.8% respectively, compared to 53.5% and 45.5% with vehicle). These non-significant results may have been due to the small sample size.*

Inflammatory lesions

*A post hoc analysis of 606 adult female patients from 2 multicenter, randomized, double-blind, vehicle-controlled, parallel group clinical studies (Tyring et al. 2018) in patients with moderate or severe acne was conducted. Patients eligible for the post hoc analysis were adult female patients aged 18 to 58 years who presented with 20 to 40 inflammatory lesions (papules, pustules, and nodules), 20 to 100 noninflammatory lesions (open and closed comedones), and two nodules or less; and an Evaluator Global Severity Score [EGSS] score of 3 (moderate) or 4 (severe). Patients were treated with either Altreno (n=236) or vehicle (n=258).

Formula Matters

The formulation of Altreno is what makes it unique. The lotion vehicle contains hydrating ingredients delivered by a honeycomb mesh to help counterbalance the regular side effects of tretinoin.*

*Like all tretinoins, Altreno may cause irritation.

Skin moisturization assessment over
24 hours (Corneometer method).*

Altreno Altreno

*Adapted from Kircik et al. (2019). Skin barrier protection of the lotion was assessed through corneometry in 30 female healthy volunteers (aged 35-65 years) over 24 hours; the vehicle was applied to the volar forearm, with an untreated site serving as a control. Measurements using Corneometer® were taken at baseline, 15 and 30 minutes, and 1, 2, 3, 8, and 24 hours post-application. Mean baseline corneometry scores 29.2 ± 2.4 and 28.1 ± 2.7 units (test material and untreated control, respectively).

Formula Matters

The formulation of Altreno is what makes it unique. The lotion vehicle contains hydrating ingredients delivered by a honeycomb mesh to help counterbalance the regular side effects of tretinoin.*

*Like all tretinoins, Altreno may cause irritation.

Skin barrier assessment over 24 hours. Transepidermal water loss method (TEWL)*

Altreno Altreno

*Adapted from Kircik et al. (2019). Skin barrier protection of the lotion was assessed through TEWL in 30 female healthy volunteers (aged 35-65 years) over 24 hours; the vehicle was applied to the volar forearm, with an untreated site serving as a control. Measurements using Tewameter® were taken at baseline, 15 and 30 minutes, and 1, 2, 3, 8, and 24 hours post-application. Mean baseline TEWL scores were 12.32 ± 0.43 and 12.42 ± 0.44 g/hm2, respectively.

Physicians surveyed agreed that the lotion vehicle (n=349):*

97%

Provides lightweight moisturization

99%

Absorbs quickly and easily into the skin

98%

Leaves no residue

99%

Does not make my skin feel greasy

98%

Has no unpleasant odor

99%

Is not tacky to the touch

*Results from a perception survey of healthcare professionals who tried the lotion vehicle.
A total of 349 prescribers with practices in the United States tried the Altreno lotion vehicle and completed the survey.1

Patients surveyed about the lotion vehicle found (n=15):

80%

Skin feels more lasting moisture and hydration than what I currently use

88%

Skin feels lasting hydration

80%

Skin feels lasting moisture

80%

Skin feels more moisturized and hydrated than with what I currently use

88%

Product absorbs quickly

Before
After

 

Actual patients from a clinical study after 12 weeks of treatment. Photos have not been retouched. Individual results may vary.

Before Baseline
after Week 12
Before Baseline 1
after Week 12
Before Baseline 1
after Week 12
Before Baseline 1
after Week 12

Photos have not been retouched. Individual results may vary.

Tolerability

*Two Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group studies comparing the efficacy and safety of Altreno lotion (tretinoin 0.05%) once daily to the lotion vehicle alone in patients 9 years and older with moderate-to-severe acne vulgaris.

Treatment-related adverse events reported by ≥1% of patients through week 12 (Altreno Lotion [n=767] vs. vehicle lotion [n=783], respectively:*

Application site:

  • Pain: 3.1% vs. 0.4%
  • Dryness: 3.7% vs. 0.1%
  • Erythema: 1.4% vs. 0.1%

*Two Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group studies comparing the efficacy and safety of Altreno Lotion (tretinoin 0.05%) once daily to the lotion vehicle alone in patients 9 years and older with moderate-to-severe acne vulgaris.

In the Tyring et al. (2018) safety population, 12/767 (1.6%) of patients in the Altreno group discontinued due to treatment emergent adverse event(s) (TEAE). None of the patients in the vehicle group discontinued due to a TEAE.*

*Two Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group studies comparing the efficacy and safety of Altreno Lotion (tretinoin 0.05%) once daily to the lotion vehicle alone in patients 9 years and older with moderate-to-severe acne vulgaris.

In the Tyring et al. (2018) safety population, 12/767 (1.6%) of patients in the Altreno group discontinued due to treatment emergent adverse event(s) (TEAE). None of the patients in the vehicle group discontinued due to a TEAE.*

*Two Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group studies comparing the efficacy and safety of Altreno Lotion (tretinoin 0.05%) once daily to the lotion vehicle alone in patients 9 years and older with moderate-to-severe acne vulgaris.

Physician
Dispense

 
 
Get Altreno now

01

Altreno Lotion 20g tube

Altreno 20g

Next Next

02

Altreno Lotion 45g tube

Altreno 45g

Next Next
 
Altreno

Indications and Usage

Altreno® (tretinoin) Lotion, 0.05% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

Important Safety Information

Altreno is for topical use only. Not for ophthalmic, oral, or intravaginal use.

Skin Irritation: Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation.

Skin Irritation

Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation. Depending upon the severity of these adverse reactions, instruct patients to use a moisturizer, reduce the frequency of the application of Altreno, or discontinue use. Avoid application of Altreno to eczematous or sunburned skin.

Ultraviolet Light and Environmental Exposure

Minimize unprotected exposure to ultraviolet light, including sunlight and sunlamps. Warn patients with frequent sun exposure and those with inherent sensitivity to sunlight to exercise caution. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

Fish Allergies

Altreno contains soluble fish proteins. Use with caution in patients with known sensitivity or allergy to fish. Advise patients to contact their healthcare provider if they develop pruritus or urticaria.

Adverse Reactions

The most common adverse reactions in clinical trials were application site dryness (4%), pain (3%), erythema (2%), irritation (1%) and exfoliation (1%).

Nursing Women

It is not known whether topical administration of tretinoin could result in sufficient systemic absorption to produce detectable concentrations in human milk. The developmental health benefits of breastfeeding should be considered along with the mother’s clinical need for Altreno and any potential adverse effects on the breastfed child from Altreno.

To report suspected adverse reactions, contact Customer Service at 1-800-321-4576 or the FDA at 1-800-FDA-1088 or fda.gov/medwatch.

View full Prescribing Information

 
Altreno

How Do I Get Altreno?

Altreno is a powerful Rx product, which means it requires a prescription. We can help you get in touch with a healthcare provider in two easy ways:

1. Online consultation
2. In-person visit

Get Started